Lilly forecasts weak fourth-quarter sales of weight-loss drug, shares slump
Eli Lilly forecast sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street estimates in the fourth quarter, sending the drugmaker's shares down more than 8% on Tuesday.
Eli Lilly was hoping weight loss drug demand would be even bigger
Eli Lilly (LLY) revised its revenue outlook on Tuesday for the fourth quarter of 2024 on weaker-than-expected demand for its popular weight-loss drugs, Zepbound and Mounjaro.
Mounjaro and Zepbound sales disappoint, and Eli Lilly’s stock is dropping
Shares of Eli Lilly and Co. slipped 0.4% in premarket trading Tuesday, after the drug maker provided a disappointing fourth-quarter revenue outlook, citing slower-than-expected growth in sales of its weight-loss drugs.
Lilly sues two medical spas over copycat weight-loss drugs
Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound.
New weight loss pill to be approved by early 2026: Eli Lilly
Eli Lilly expects its experimental weight loss pill, orforglipron, to receive approval as early as next year, CEO David Ricks told Bloomberg Jan. 13, according to a Wall Street Journal report.
Lilly forecasts weak sales of weight-loss drug, shares slump
STORY: Shares of Eli Lilly tumbled as much as 8% on Tuesday, after the company forecast weaker-than-expected fourth-quarter sales of its weight-loss drug Zepbound.The decline put the stock on track for its worst single-day drop in nearly four years.
Eli Lilly CEO tells Bloomberg TV company sees weight loss pill approval in 2026
Eli Lilly (LLY) expects that its experimental weight loss pill will get approved as soon as early next year, CEO David Ricks said in an
Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity and diabetes drugs.
Hims & Hers in focus as Eli Lilly obesity drug sales disappoint
Eli Lilly (NYSE:LLY) shares sold off on Tuesday after the Indiana-based pharma giant's Q4 and 2024 preliminary sales results for its obesity therapy tirzepatide fell short of Street forecasts. Novo Nordisk (NVO),
Eli Lilly Tumbles On Lowered Guidance As Weight-Loss Drug Sales Slow
Eli Lilly stock fell on lowered Q4 guidance amid slower-than-expected sales for its Zepbound and Mounjaro weight loss drugs.
Lilly shares on track for worst day since 2021 after downbeat Zepbound sales forecast
Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...
FierceBiotech1d
Kailera reports Zepbound-rivaling weight loss in phase 2 obesity trial
Fresh from a $400 million series A round, Kailera Therapeutics has shown off phase 2 data on an obesity candidate it believes ...
Maker of weight-loss drugs to ask Trump to pause price negotiations: Report
Eli Lilly and other drugmakers are reportedly planning to urge the Trump administration to pause Medicare drug-price ...
FDA Approves Weight-loss Drug Zepbound For Sleep Apnea – Will Insurance Cover This $1000-Per-Month Medication?
Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...
Medicine Buffalo1d
UB pharmacy professor discusses pros and cons of popular weight-loss drugs
Nicole Albanese, PharmD, discusses the science behind weight-loss drugs, their potential to treat other addictions as well as ...
Hosted on MSN10h
Lilly forecasts weak sales of weight-loss drug in fourth quarter
(Reuters) - Eli Lilly expects sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to ...
Some GLP-1s Achieve More Weight Loss Than Others: Study
By comparison, the FDA-approved drug liraglutide only resulted in just under 6% weight loss after 26 weeks, the researchers found. Common adverse side effects from the drugs included nausea, vomiting, ...